Video Experimental Relacionado
Updated: May 15, 2026
11:44
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
Captura dirigida por ATP de un medicamento bioactivo a base de hierbas en la tRNA sintetasa humana
Huihao Zhou1, Litao Sun, Xiang-Lei Yang
1The Skaggs Institute for Chemical Biology, Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Nature
|December 25, 2012
Resumen
La halofuginona (HF) es un inhibidor dependiente del ATP de la prolyl-tRNA sintetasa humana (ProRS). La estructura revela que HF imita la prolina y el tRNA, uniéndose simultáneamente a dos sitios en ProRS.
Área de la Ciencia:
- Biología Estructural Biología estructural.
- La bioquímica es la bioquímica.
- Descubrimiento de Drogas Descubrimiento de Drogas
Sus antecedentes:
- Febrifugina, de la hierba Chang Shan, tratada históricamente para la malaria.
- La halofuginona (HF), un derivado de la febrifugina, muestra un potencial terapéutico en el cáncer y las enfermedades fibróticas.
- La HF inhibe la diferenciación celular T(H)17 al dirigirse a la sintetasa de prolyl-tRNA humano (ProRS), lo que lleva a la acumulación de tRNA sin carga.
Objetivo del estudio:
- Para dilucidar el mecanismo estructural de la inhibición de la halofuginona (HF) en el ProRS humano.
- Comprender el papel del ATP en la unión e inhibición del HF.
- Explorar el potencial para el desarrollo de nuevos inhibidores dirigidos a las sintetasas.
Principales métodos:
- Cristalografía de rayos X para determinar la estructura 2.0 Å de HF unido al ProRS. humano.
- Pruebas bioquímicas para investigar la inhibición dependiente de ATP.
Principales resultados:
- La estructura revela orientaciones de unión de ATP HF para ocupar simultáneamente dos sitios de unión de sustrato distintos en ProRS.
- Una parte de la HF imita la prolina, mientras que otra imita el extremo 3' del tRNA.
- HF actúa como un nuevo inhibidor dependiente de ATP, lo que demuestra un mecanismo de unión de doble sitio.
Conclusiones:
- La halofuginona (HF) es un inhibidor de doble sitio dependiente de ATP del ProRS. humano.
- Los hallazgos estructurales sugieren un mecanismo potencialmente similar para la febrifugina en el tratamiento de la malaria.
- Esta estrategia de orientación de doble ubicación puede ser aplicable para el desarrollo de inhibidores contra otras sintetasas.
Videos de Conceptos Relacionados
01:48ATP Synthase: Mechanism
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
02:26tRNA Activation
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
02:36Transfer RNA Synthesis
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...